ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · IEX Real-Time Price · USD
64.20
+1.38 (2.20%)
Jun 25, 2024, 1:25 PM EDT - Market open

Company Description

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals.

ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals logo
Country United States
Founded 2001
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 642
CEO Nikhil Lalwani

Contact Details

Address:
210 Main Street West
Baudette, Minnesota 56623
United States
Phone (218) 634-3500
Website anipharmaceuticals.com

Stock Details

Ticker Symbol ANIP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001023024
CUSIP Number 00182C103
ISIN Number US00182C1036
Employer ID 58-2301143
SIC Code 2834

Key Executives

Name Position
Nikhil Lalwani President, Chief Executive Officer and Director
Stephen P. Carey Senior Vice President of Finance and Chief Financial Officer
Chad Gassert Senior Vice President of Corporate Development and Strategy
Christopher K. Mutz Senior Vp and Head of Rare Disease
Ori Gutwerg Senior Vice President of Generics
Muthusamy Shanmugam MS R.Ph. Head of Research & Development, Chief Operating Officer of Novitium Operations and Director
James G. Marken Senior Vice President of Operations and Product Development
Meredith W. Cook Senior Vice President, General Counsel and Corporate Secretary
Krista L. Davis Senior Vice President and Chief Human Resources Officer
Elizabeth Powell J.D. Chief Compliance Officer and Head of Legal of Rare Disease

Latest SEC Filings

Date Type Title
Jun 24, 2024 8-K Current Report
Jun 21, 2024 144 Filing
Jun 20, 2024 144 Filing
Jun 18, 2024 144 Filing
Jun 17, 2024 144 Filing
Jun 5, 2024 8-K Current Report
Jun 4, 2024 144 Filing
May 23, 2024 8-K Current Report
May 20, 2024 144 Filing
May 17, 2024 144 Filing